Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 12.62M | 10.65M | 0.00 | 12.50M | 0.00 | 0.00 |
Gross Profit | 13.26M | 10.65M | -27.23M | 9.23M | -3.30M | -2.93M |
EBITDA | -25.31M | -25.54M | -41.13M | -42.38M | -51.35M | -31.37M |
Net Income | -16.70M | -63.56M | -43.04M | -36.00M | -52.51M | -32.63M |
Balance Sheet | ||||||
Total Assets | 102.70M | 48.47M | 46.08M | 89.44M | 137.17M | 62.06M |
Cash, Cash Equivalents and Short-Term Investments | 90.39M | 34.56M | 36.04M | 75.84M | 101.85M | 49.18M |
Total Debt | 7.51M | 8.47M | 3.38M | 5.60M | 7.79M | 9.60M |
Total Liabilities | 55.58M | 69.85M | 8.14M | 13.43M | 27.47M | 14.77M |
Stockholders Equity | 47.11M | -21.38M | 37.94M | 76.00M | 109.70M | 47.29M |
Cash Flow | ||||||
Free Cash Flow | -18.73M | -17.65M | -40.76M | -44.87M | -50.08M | -29.97M |
Operating Cash Flow | -18.66M | -17.63M | -40.36M | -44.15M | -48.81M | -29.10M |
Investing Cash Flow | -64.00K | -26.00K | 51.72M | 38.31M | -77.71M | -15.07M |
Financing Cash Flow | 71.35M | 16.18M | 276.00K | -2.56M | 124.63M | 50.05M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
55 Neutral | $77.76M | 12.00 | -8.31% | ― | -9.33% | 97.60% | |
52 Neutral | $94.18M | ― | -69.71% | ― | 303.47% | 73.70% | |
51 Neutral | $85.64M | ― | 149.62% | ― | -5.22% | 82.06% | |
46 Neutral | C$217.46M | -0.36 | -24.12% | 3.15% | 19.33% | -0.50% | |
44 Neutral | $47.49M | ― | -96.35% | ― | -52.76% | 43.40% | |
43 Neutral | $95.56M | ― | -130.27% | ― | ― | 35.81% | |
33 Underperform | $150.88M | 10.98 | 11.85% | ― | ― | ― |
On March 24, 2025, Surrozen, Inc. entered into a Securities Purchase Agreement with institutional and accredited investors for a two-tranche private placement of shares and warrants, raising approximately $76.4 million in the first tranche. The second tranche, contingent on FDA clearance of an Investigational New Drug Application by October 31, 2026, could bring an additional $98.6 million. Additionally, Tim Kutzkey was appointed as a Class I director on March 26, 2025, bringing extensive experience in biotechnology and venture capital.